Skip to content
Screener

Similar metrics at other companies

Ducommun logo
DCOElectronic Systems — 2027
$9.29M0.0%
Ducommun logo
DCOStructural Systems — 2027
$7.44M0.0%
Ducommun logo
DCOElectronic Systems — 2026
$9.29M0.0%
Ducommun logo
DCOStructural Systems — 2026
$7.44M-0.3%
Ducommun logo
DCOElectronic Systems — 2028
$9.29M0.0%
Ducommun logo
DCOElectronic Systems — 2029
$5.28M-43.2%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$882.2M-22.5%
Enterprise value$736.79M-26.8%
P/E18.4×-13.0×
P/S1.1×-0.5×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Years ended December 31,Jornay PMAzstarysBelbucaSymproicTotal
2026$41,915$27,283$37,695$3,643$110,536
202783,82954,5677,285145,681
202883,82954,5677,285145,681
202983,82954,5677,285145,681
203083,82954,5677,285145,681
Thereafter104,783381,9696,072492,824
Remaining amortization expense$482,014$627,520$37,695$38,855$1,186,084

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s belbuca — 2027?
Collegium Pharmaceutical, Inc. (COLL) reported belbuca — 2027 of $0 in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s belbuca — 2027 changed year-over-year?
Collegium Pharmaceutical, Inc.'s belbuca — 2027 decreased by 100.0% year-over-year, from $75.39M to $0.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — 2027?
Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — 2027 has grown at a -0.2% compound annual growth rate (CAGR), from $303.67M to $301.57M.
What does belbuca — 2027 mean?
The projected amortization expense specifically allocated to Belbuca-related intangible assets for the fiscal year 2027. This forward-looking metric assists in modeling long-term earnings and assessing the remaining useful life of the asset.

Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude